论文部分内容阅读
抗癌新药ＢＢ－２５ｌ６进人Ⅱ临床试验英国生物技术公司研究的口服抗癌药（ＢＢ－２５１６），已在英国结束了Ⅰ期临床试验，现已在英国和美国进入Ⅱ期临床，ＢＢ－２５１６为首次在癌症患者中使用口服基质的金属蛋白酶抑制剂（ＭＭＰｌ）。英国生物技术公司声称，该药已...
The New Anticancer Drug BB-25l6 Into Human Clinical Trials The oral anticancer drug (BB-2516) studied by British biotech company has ended Phase I clinical trials in the UK and has now entered Phase II clinical trials in the United Kingdom and the United States. BB- 2516 is the first use of the oral matrix metalloproteinase inhibitor (MMP1) in cancer patients. British biotechnology company claims that the drug has ...